InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
5,505.00
(
-0.71%
)
US TECH 100
19,000.00
(
-0.94%
)
Dow Jones
40,287.53
(
-0.93%
)
Brent Oil
81.88
(
0.00%
)
Bitcoin
66,593.52
(
-0.19%
)
Post# of 252642
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 831
Posts 120081
Boards Moderated 16
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 98716

Sunday, 10/31/2010 10:50:56 PM

Sunday, October 31, 2010 10:50:56 PM

Post# of 252642
JNJ/Medivir report that 79-86% of TMC435 patients in the four non-control arms of the phase-2b PILLAR study in the first-line setting stopped treatment at 24 weeks according to the response-guided protocol in the study:

http://finance.yahoo.com/news/Week24-Interim-Results-From-prnews-47168379.html?x=0&.v=1

The protocol of this study required that patients have undetectable VL from week 4 to week 20 in order to stop treatment at 24 weeks.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up